Johnson & Johnson Innovative Medicine

Celebrating Two Years of JLABS Singapore Advancing Healthcare Innovation in Asia Pacific!   We proudly join JLABS, Johnson & Johnson’s global incubator network, in recognizing the second anniversary of JLABS Singapore!    Established in collaboration with the Singapore Economic Development Board (EDB), JLABS Singapore provides a dynamic ecosystem for emerging companies to transform scientific discoveries into solutions that improve patients’ lives.    We invite you to explore highlights from the past year — including key community achievements and success stories. Read the anniversary blog article here: https://lnkd.in/gFWCKigh  

At Johnson & Johnson, we’re committed to transforming how depression is treated. Depression is projected to become the leading cause of disability worldwide by 2030, and for millions of people living with major depressive disorder (MDD), current treatments often fall short. Discover how our teams are advancing innovative therapies that address the complexity of MDD and bring hope to the patients who need it most: https://lnkd.in/gykt7CnE

We were honored to take part in The Balm In Gilead, Inc.’s #HealthyChurches2030 Virtual Conference, in collaboration with Bristol Myers Squibb, where patients and community leaders came together for a symposium titled “The Importance of Broad Participation in Clinical Trials.”    The discussion explored how representation, education and trust in clinical research can help advance cardiovascular care, particularly for those affected by stroke.    A special thank-you to Dr. Imama A. Naqvi and Dr. ShantaQuilette (Dr. Q) Develle, MBA, CPLC, MH, EA, a heart attack and stroke survivor and health advocate, for sharing their experiences and perspectives on how participation and awareness in research can drive better outcomes for patients everywhere.    Learn more about how our ongoing collaboration is helping reimagine care for cardiovascular patients: https://bit.ly/489YmoO     #CardiovascularHealth #StrokeAwareness #TheBalmInGilead 

#PHridayPHacts: #PulmonaryHypertension can affect adults and children of all ages, but its impact is not the same for everyone. Women are more than three times as likely as men to develop #PulmonaryArterialHypertension (PAH), and people of color often face poorer health outcomes. In recognition of #PHAwarenessMonth, hear from Gerry as she shares her experience living with PAH and the importance of having support. #PassionAdvancementHope

The whole-genome sequencing of nearly 500,000 UK Biobank participants, recently published in Nature, marks a major leap forward for understanding human disease. As Trevor Howe shares in his latest blog, the depth of this dataset is transforming how we identify and validate drug targets, de-risk discovery, and accelerate precision medicine across Johnson & Johnson’s R&D efforts. This achievement is also a powerful example of what collaborative science can unlock. By combining UK Biobank’s multi-omic insights with our internal expertise and partnerships, we’re advancing data-driven innovation to deliver the next generation of treatments. Read the blog here: https://lnkd.in/gaGEnKXn

This November, we join the #PulmonaryHypertension (PH) community in celebrating #PHAwarenessMonth and supporting the Pulmonary Hypertension Association’s (PHA) theme, “EmPHasize Your Health.” From raising awareness to advocating for better care, we can make a lasting impact for those living with PH. Visit the PHA’s site to get involved: https://lnkd.in/gsRiABSP #PassionAdvancementHope #PulmonaryArterialHypertension

Johnson & Johnson's Joshua Bauml, M.D., Vice President, Lung Cancer Disease Area Stronghold Leader, shares his commitment to getting #InFrontofCancer by advancing treatment options for #LungCancer, the world’s leading cause of cancer mortality.    This #LungCancerAwarenessMonth, join us in raising awareness about the urgent need to advance new standards of care for this disease: https://lnkd.in/gPM436jC #JNJOncology

This week at the Inflammatory Skin Disease Summit (ISDS), we’re presenting new findings that showcase our continued advancements in treating psoriatic arthritis and reinforcing our commitment to transformative science.    Every data point reflects our mission to reimagine what’s possible for people living with chronic inflammatory diseases.  Learn more: http://bit.ly/3JPRTGn   #JNJImmunology #ISDS2025 #InnovationInImmunology  

#BREAKINGNEWS We have entered into an agreement to acquire Halda Therapeutics, a clinical stage biotechnology company with a highly differentiated treatment for prostate cancer. This builds on Johnson & Johnson’s nearly two decades of innovation in the disease and provides a novel technology platform capable of developing the next generation of highly targeted oral treatments for multiple solid tumors, including breast and lung cancers. Read our press release to learn more: https://lnkd.in/emZB9nHQ #JNJOncology #ProstateCancer #Growth #Innovation

As our understanding of lung cancer deepens, the ways we treat it continue to evolve. Here at Johnson & Johnson, our Interventional Oncology team is working to redefine what’s possible in cancer care through intratumoral drug treatments delivered directly into solid tumors, with a focus on lung cancer, the leading cause of cancer-related deaths worldwide. This integration of drugs and technology represents a bold path forward in improving the standard of cancer care for patients. #InterventionalOncology #LCAM